Efficacy and Tolerability of Xalatan in Patients
Overview
Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.
Full Title of Study: “Observational Study Assessing The Efficacy And Tolerability Of Xalatan™ In Patients With Open Angle Glaucoma And /Or Ocular Hypertension.”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: December 2007
Detailed Description
– Efficacy data not collected or analyzed – Safety and tolerability of Xalatan assessed NA
Interventions
- Drug: Xalatan 0.005% eye drops
- ophthalmic solution dosed once daily for 3 months
Arms, Groups and Cohorts
- Study Drug – Xalatan 0.005% eye drops
Clinical Trial Outcome Measures
Primary Measures
- Intraocular Pressure
- Time Frame: Screening, 10 days, 4 weeks and 12 weeks after beginning treatment
- Intraocular pressure was measured at each visit
- Humphrey Perimetry Visual Field
- Time Frame: Visits 1 and 4
- Analysis of visual field deficits for abnormalities.
Participating in This Clinical Trial
Inclusion Criteria
- Patient with ocular hypertension at least 22mg Hg – Patient must be over 18 years old Exclusion Criteria:
- None listed in the protocol
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 65 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Pfizer’s Upjohn has merged with Mylan to form Viatris Inc.
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Pfizer CT.gov Call Center, Study Director, Pfizer
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.